Background and Purpose:Shoulder pain is a prevalent condition in older adults. Some authors associate nonspecific shoulder pain with myofascial trigger points (MTrPs) in the infraspinatus muscle. Dry needling is recommended to relieve the MTrP pain of shoulders in the short term (<9 days). Active MTrPs dry needling improves shoulder pain and the irritability of the satellite MTrPs in the referred pain area. Nociceptive activity at a latent MTrP may influence motor activity and the sensitivity of MTrPs in distant muscles at a similar segmental level. Therefore, this study aimed to evaluate dry needling on 1 latent MTrP, in conjunction with 1 active MTrP, in the infraspinatus muscle of older adults with nonspecific shoulder pain.Methods:A single-center, randomized, single-blinded, controlled study (NCT02032602) was carried out. Sixty-six patients aged 65 years and older with trigger points in the ipsilateral infraspinatus of the painful shoulder were randomly assigned to (1) of (2) treatment groups. A session of dry needling on the infraspinatus was performed in (1) the most hyperalgesic active and latent MTrP or (2) only the most hyperalgesic active MTrP. The Numeric Rating Scale, the pressure pain threshold (primary outcome) on the anterior deltoid and extensor carpi radialis brevis latent MTrPs, and grip strength were assessed before, after, and 1 week after the intervention.Results:Statistically significant differences in the reduction of pain intensity (P ≤ .001; η2 = 0.159-0.269; d = 1.017-1.219) and the increase of pressure pain threshold (P < .001; η2 = 0.206-0.481; d = 0.870-1.924) were found for the (1) treatment group immediately and 1 week postintervention. Nevertheless, no statistical significant differences were found in grip strength (P >. 05; η2 = 0.006-0.033; d = 0.158-0.368).Conclusions:One dry needling intervention of the latent MTrP associated with the key active MTrP of the infraspinatus reduces pain intensity and the irritability of the satellite MTrPs located in the referred pain area in the short term in older adults with nonspecific shoulder pain.

Abstract:Laughter is increasingly present in biomedical literature, both in analytical neurological aspects and in applied therapeutic fields. The present paper, bridging between the analytical and the applied, explores the potential of a relevant variable of laughter's acoustic signature-entropy-in the detection of a widespread mental disorder, depression, as well as in gauging the severity of its diagnostic. In laughter, the Shannon-Wiener entropy of the distribution of sound frequencies, which is one of the key features distinguishing its acoustic signal from the utterances of spoken language, has not been a specific focus of research yet, although the studies of human language and of animal communication have pointed out that entropy is a very important factor regarding the vocal/acoustic expression of emotions. As the experimental survey of laughter in depression herein undertaken shows, it was possible to discriminate between patients and controls with an 82.1% accuracy just by using laughter's entropy and by applying the decision tree procedure. These experimental results, discussed in the light of the current research on laughter, point to the relevance of entropy in the spontaneous bona fide extroversion of mental states toward other individuals, as the signal of laughter seems to imply. This is in line with recent theoretical approaches that rely on the optimization of a neuro-informational free energy (and associated entropy) as the main "stuff" of brain processing.

Background: Systemic hypertension (SH) is common in dogs and humans with hypercortisolism and can persist after treatment. Objectives: To evaluate changes in prevalence of SH and systolic blood pressure (SBP) in dogs with pituitary-dependent hyperadrenocorticism (PDH) during the first year of trilostane treatment, its relationship with disease control and selected laboratory variables, and their response to antihypertensive treatment. Animals: Fifty-one dogs with PDH treated with trilostane Q12h. Methods: Prospective case series study. Dogs were evaluated at diagnosis (T0) and 1, 3, 6, and 12 months (T12). Dogs were classified as nonhypertensive (SBP < 160 mm Hg) or hypertensive (SBP≥160 mm Hg) and subclassified according to target organ damage (TOD) risk. Hypertensive dogs were treated with benazepril and, if control of SH was not achieved, amlodipine was added. Results: Prevalence of SH decreased from T0 (36/51) to T12 (17/37; P = .01). Changes in SBP during the study were influenced by the risk of TOD at T0. In severely hypertensive (SBP ≥ 180 mm Hg) dogs, the decrease in SBP was more pronounced whereas in normotensive (SBP < 140 mm Hg) dogs SBP increased slightly (P = .00). Blood pressure was not associated with disease control. Antihypertensive treatment was needed in 31/51 dogs, and in 13/31 dogs additional SH control with amlodipine was required. One third of nonhypertensive dogs at T0 required treatment with benazepril because SH developed during follow-up. Conclusions and Clinical Importance: In dogs with PDH, SBP should be measured at every visit, regardless of disease control or SBP at diagnosis. More than 1 drug may be necessary to manage SH in affected dogs.

No abstract

No abstract